Hexarelin Research in 2026: The Growth Hormone Secretagogue With Three Decades of Human Data — and Still No Approval

887 grams per mole. Six amino acids. One D-2-methyl-tryptophan substitution that changed everything about how it binds. That’s Hexarelin in a single molecular snapshot — and it’s also the shortest possible answer to why researchers keep coming back to a compound that was first tested in humans back in the early 1990s and never once cleared the FDA.

For laboratory and in-vitro research use only. Hexarelin is not a drug, has not been evaluated by the FDA for safety or efficacy, and is not sold, labeled, or intended for human or veterinary use, administration, or consumption. Nothing below is a how-to guide — it’s a look at what the published research actually says, and how to buy the compound without getting burned in the process.

If you’ve spent any time comparing growth-hormone secretagogues — GHRP-6, GHRP-2, Ipamorelin, and Hexarelin all sitting in the same tab group — you already know the challenge. The marketing copy across most vendor sites reads almost identically: same purity claim, same stock photo of a lyophilized vial, same vague “may support” language. What actually separates these compounds is buried in decades of endocrinology journals most buyers never open. So let’s open them.

Here’s a scenario a lot of research buyers will recognize: you finally track down a supplier with a decent price on Hexarelin, place the order, and the vial that shows up has no lot number on the label and no COA in the box — just a generic “99% pure” sticker that could belong to literally any SKU in their catalog. Now you’re stuck emailing support and hoping someone responds before your protocol timeline slips. It’s frustrating, it’s common, and it’s completely avoidable if you know what to check before you check out. That’s exactly what this guide walks through — the actual research on Hexarelin, why it never became a marketed drug despite genuine human trials, and how to make sure the batch you’re buying is what the label says it is.

What Is Hexarelin, Exactly?

Hexarelin — also called Examorelin in the pharmacological literature — is a synthetic hexapeptide built as an analog of growth hormone-releasing peptide-6 (GHRP-6). Structurally, it’s His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2: six amino acids, one modification (a D-2-methyl-tryptophan swap) that changes how tightly it binds its target receptor compared to unmodified GHRP-6.

The compound carries CAS number 140703-51-1, a molecular formula of C47H58N12O6, and a molecular weight of roughly 887 g/mol. It’s not an approved pharmaceutical anywhere in the world, and it’s not a dietary supplement — it exists squarely in the research-chemical category, sold to labs and institutions studying its mechanisms, not to end consumers looking for a shortcut.

What makes Hexarelin genuinely unusual among research peptides is its history. Most compounds in this space have thin human data — a handful of small trials, if any. Hexarelin has the opposite problem: a real body of 1990s-era human pharmacokinetic studies, and it still never made it to market. Why? Keep reading.

What the Research Actually Shows

It’s a potent activator of the growth hormone axis

Hexarelin was characterized early on as an agonist at GHS-R1a — the growth hormone secretagogue receptor, more commonly known as the ghrelin receptor — on pituitary somatotroph cells. Human dose-response research from the 1990s tested intravenous, subcutaneous, and even intranasal administration, and researchers directly compared its GH-releasing potency against growth hormone-releasing hormone (GHRH) itself in the same study subjects (Ghigo et al.). That’s not a small thing — it means Hexarelin’s activity profile in humans is documented in ways most research peptides simply aren’t.

The cardioprotective pathway nobody expects

Here’s the part that surprises most people the first time they read the literature: a meaningful chunk of Hexarelin research has nothing to do with growth hormone at all. Preclinical studies identified a second binding site — the CD36 receptor on cardiac tissue — through which Hexarelin appears to act completely independently of the GH axis. In rat models of experimental myocardial infarction, Hexarelin administration was associated with improved measures of left-ventricular function compared to untreated controls (Cittadini et al.), and a separate ischemia/reperfusion injury model linked Hexarelin exposure to interleukin-1 signaling changes in cardiomyocytes (Mao et al.). Why would a growth hormone peptide have a cardiac-specific mechanism at all? That’s still an open, active research question — and it’s a big part of why Hexarelin keeps showing up in comparative secretagogue studies years after its GH-axis pharmacology was already well characterized.

It doesn’t act alone — cortisol and prolactin come along for the ride

Multiple human studies recorded that Hexarelin administration triggers more than just a GH pulse — cortisol and prolactin rise alongside it. Researchers used that multi-hormone signature to compare Hexarelin’s activity against corticotropin-releasing hormone and against GHRH combined with arginine or pyridostigmine, across different subject populations including elderly adults and short-stature pediatric cohorts (Arvat et al.). It’s a reminder that “GH secretagogue” is a simplification — the actual endocrine picture is more layered than a single-hormone story.

The response fades with continuous exposure

A recurring finding across the GHRP literature, Hexarelin included, is desensitization: the GH response attenuates with sustained receptor exposure over time. This is a well-documented pharmacodynamic pattern, and it shapes how researchers design longer protocols and interpret data collected over multiple weeks rather than single-dose windows.

So why isn’t it an approved drug?

This is the question that should stop every buyer for a second. A compound with genuine 1990s human pharmacology data, studied across multiple research groups, in patients ranging from healthy adults to those with GH-axis abnormalities — and it still never advanced to regulatory approval or commercial therapeutic development. No pharmaceutical sponsor has an active FDA pathway for it today. That gap between “extensively studied in humans” and “approved for use” is the single most important thing to understand about Hexarelin’s current legal and commercial status, and it’s exactly why it’s sold as a research chemical rather than a prescription product.

Why Hexarelin Is Still “Research Use Only” — And Why That Matters More Than It Sounds

Hexarelin, listed under its INN Examorelin, sits explicitly on the World Anti-Doping Agency’s Prohibited List under category S2.2.4, “Growth Hormone Releasing Peptides (GHRPs)” — the same category covering GHRP-2 and GHRP-6 . Separately, the FDA added GHRP-2 and GHRP-6 — Hexarelin’s closest structural relatives — to its list of bulk drug substances presenting significant safety risks for compounding, effective September 29, 2023 (FDA bulk substances list). Hexarelin itself isn’t named on that specific FDA list as of this writing, but it shares the exact mechanism and regulatory profile of the compounds that are — worth remembering before anyone assumes “not explicitly listed” means “not scrutinized.”

This isn’t legal trivia. It’s the difference between a supplier who understands what they’re selling and one who’s one compliance review away from a problem. Demand for research-grade growth-hormone-secretagogue peptides has grown alongside a broader boom in peptide research: the global peptide therapeutics market was valued at roughly $140.9 billion in 2025 and is projected to reach $294.6 billion by 2033. Labs across the United States, Canada, Germany, and France are all competing for the same well-characterized material, and that growth has attracted plenty of vendors who treat documentation as optional. It isn’t. Browse our full Growth Hormone Research category to see how every batch we carry is verified before it ever ships — buyers outside the U.S. remain responsible for checking their own country’s import and research-chemical regulations before ordering.

The Real Buying Problem: Purity, COAs, and Trust

Ask yourself this: if two vendors both list “Hexarelin, 99% purity,” and only one of them can produce a batch-specific Certificate of Analysis on request, which one would you actually trust with your next protocol? A purity number printed on a product page is marketing copy. A COA tied to the exact lot sitting in your freezer is data — and treating those two things as interchangeable is how research budgets quietly get wasted on material nobody actually verified.

What a real COA needs to show

At minimum: the batch or lot number matching your vial, HPLC-determined purity reported as an actual number (not just asserted as “99%+”), mass spectrometry confirming molecular weight against the expected ~887 g/mol, and a dated signature from the lab that ran the test. If a vendor can’t produce that before you pay, that tells you what you need to know.

How NexaPeptideLabs verifies every Hexarelin batch

We order Hexarelin in defined production batches and require independent third-party HPLC and mass spectrometry verification before any batch is released for sale, consistent with our COA reporting standards. Every certificate is tied to its specific lot — never pooled across production runs — and it’s posted at checkout, not hidden behind a support ticket. If you’re comparing secretagogue options for a GH-axis or cardiac-signaling protocol, our Hexarelin research peptide page has the current batch documentation posted, alongside GHRP-6 and GHRP-2 listings carrying the same standard. Every order is subject to our research use and policies page, so review that before you check out.

How to Store Hexarelin for Laboratory Use

Lyophilized Hexarelin should be kept at −20°C, sealed, and protected from light and moisture. Once reconstituted for in-vitro assay purposes, minimize freeze-thaw cycling, aliquot only what a given experiment requires, and store aliquots at the temperature specified on that batch’s COA — stability data is lot-dependent, so don’t assume this quarter’s batch behaves exactly like last quarter’s. A standard chest freezer held at a steady −20°C generally protects peptide integrity better than a frost-free unit with fluctuating internal temperatures, even though the frost-free option looks more convenient on the shelf.

FAQs About Hexarelin

What is Hexarelin?

It’s a synthetic hexapeptide and GHRP-6 analog, studied as a growth hormone secretagogue acting on the GHS-R1a (ghrelin) receptor, with a documented history of human pharmacokinetic research dating to the 1990s.

What is Hexarelin used for in research?

Published literature has investigated it for GH-axis secretagogue activity, a GH-independent cardioprotective signaling pathway involving the CD36 receptor, and comparative endocrine research involving cortisol and prolactin co-release. These are research findings, not evidence of effects in any clinical use case.

Is Hexarelin legal to buy for research?

It can currently be purchased as a research chemical in the U.S. when sold and used strictly for laboratory or in-vitro purposes. It’s not an approved drug or supplement, and buyers are responsible for complying with their own institution’s and jurisdiction’s research-chemical regulations.

Is Hexarelin FDA approved?

No. Despite a genuine body of human pharmacology studies, it was never advanced to regulatory approval or commercial therapeutic development.

Is Hexarelin the same as GHRP-6?

No. It’s a modified analog of GHRP-6, carrying a D-2-methyl-tryptophan substitution that changes its receptor-binding characteristics and, per the literature, its potency profile.

What’s the CAS number for Hexarelin?

140703-51-1.

Does Hexarelin show up on anti-doping lists?

Yes. It’s explicitly named as Examorelin under the World Anti-Doping Agency’s S2.2.4 category for growth hormone-releasing peptides, alongside GHRP-2 and GHRP-6.

Has Hexarelin actually been tested in humans?

Yes — unlike many research peptides, it has a genuine body of published 1990s-era human dose-response and pharmacokinetic studies. That data never translated into a marketed drug, which is part of what makes its regulatory story unusual.

Why is a compound with human trial data still sold as research-use-only?

Because historical pharmacology studies aren’t the same thing as an approved drug. No sponsor pursued Hexarelin through FDA review to completion, so it has no approved indication and no legal path to human marketing today.

What does a Certificate of Analysis actually verify?

A COA documents a specific batch’s identity and purity — typically HPLC purity analysis plus mass spectrometry confirming molecular weight — tied to that lot’s number and test date. It’s the only real way to know a vial contains what the label claims.

How is Hexarelin different from Ipamorelin?

Both act through the GHS-R1a pathway, but they differ in receptor selectivity and hormone co-release: Ipamorelin’s literature emphasizes more selective GH-axis activity with minimal cortisol/prolactin elevation, while Hexarelin’s research includes the additional CD36-mediated cardiac signaling pathway described above.

How should Hexarelin be stored?

At −20°C, sealed, protected from light and moisture, with reconstituted material aliquoted and stored per the specific batch’s technical data sheet to limit freeze-thaw degradation.

Where can I buy Hexarelin with a verified COA?

NexaPeptideLabs posts batch-specific, third-party-verified COAs at checkout on its Hexarelin product listing — worth comparing against any vendor that won’t show documentation before you pay.